Trade Summary

5 days ago, van Houte Hans, serving as Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 2,845 shares at $23.38 per share, for a total transaction value of $66,524.07. Following this transaction, van Houte Hans now holds 44,927 shares of NRIX.

This sale represents a 5.96% decrease in van Houte Hans's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, July 30, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, July 30, 2026 at 5:58 PM ET, meaning the disclosure happened on the same day as the trade.

Nurix Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.